Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Survival and proliferation of myeloma cells rely on splicing factor RBM39, and targeting RBM39 or MEK5 synergistically increases the cytotoxicity of bortezomib in myeloma cells via the inhibition of p65.”
Authors: Jia Liu et al.
More posts featuring Robert Orlowski.
